ROIV

Nasdaq

Roivant Sciences Ltd.

Latest disclosureOctober 5, 2026

Insider score Why 0?: 0/ 100
Qualifying buys · 30d: $0

0 purchases · 46 sales

Price by TradingView

Insider transactions 137

Limited filing history

Filters

Last 30 daysNo qualifying insider buying. Sales: $9.16M by 3 insiders.

Showing the first 6 of 46 trades on this page.

Sale disclosed

Melissa B. Epperly

Director

Common Shares

Reported value: $607.95K
Reported price: $36.08 / share

Sale disclosed

Melissa B. Epperly

Director

Common Shares

Reported value: $32.91K
Reported price: $36.57 / share

Sale disclosed

Eric Venker

President & Immunovant CEO

Common Shares

Reported value: $7.32M
Reported price: $36.62 / share

Sale disclosed

Melissa B. Epperly

Director

Common Shares

Reported value: $172K
Reported price: $39.65 / share

Sale disclosed

Melissa B. Epperly

Director

Common Shares

Reported value: $24.23K
Reported price: $40.38 / share

Sale disclosed

Meghan Fitzgerald

Director

Common Shares

Reported value: $186.97K
Reported price: $39.68 / share

Sale disclosed

Meghan Fitzgerald

Director

Common Shares

Reported value: $16.18K
Reported price: $40.45 / share

Sale disclosed

Meghan Fitzgerald

Director

Common Shares

Reported value: $798K
Reported price: $39.90 / share

Sale disclosed

Eric Venker

President & Immunovant CEO

Common Shares

Reported value: $5.92M
Reported price: $35.63 / share

Sale disclosed

Eric Venker

President & Immunovant CEO

Common Shares

Reported value: $1.23M
Reported price: $36.44 / share

Sale disclosed

Mayukh Sukhatme

President & CIO

Common Shares

Reported value: $6.43M
Reported price: $37.17 / share

Sale disclosed

Mayukh Sukhatme

President & CIO

Common Shares

Reported value: $653.46K
Reported price: $37.30 / share

Sale disclosed

Mayukh Sukhatme

President & CIO

Common Shares

Reported value: $5.28M
Reported price: $36.48 / share

Sale disclosed

Mayukh Sukhatme

President & CIO

Common Shares

Reported value: $8.81M
Reported price: $36.23 / share

Sale disclosed

Mayukh Sukhatme

President & CIO

Common Shares

Reported value: $10.32M
Reported price: $36.25 / share

Sale disclosed

Mayukh Sukhatme

President & CIO

Common Shares

Reported value: $3.85M
Reported price: $36.59 / share

Sale disclosed

Mayukh Sukhatme

President & CIO

Common Shares

Reported value: $1.18M
Reported price: $37.18 / share

Sale disclosed

Eric Venker

President & Immunovant CEO

Common Shares

Reported value: $6.99M
Reported price: $34.95 / share

Sale disclosed

Meghan Fitzgerald

Director

Common Shares

Reported value: $349K
Reported price: $34.90 / share

Sale disclosed

Melissa B. Epperly

Director

Common Shares

Reported value: $514.87K
Reported price: $34.32 / share

Sale disclosed

Melissa B. Epperly

Director

Common Shares

Reported value: $95.38K
Reported price: $34.71 / share

Sale disclosed

Keith S. Manchester

Director

Common Shares

Reported value: $10.2M
Reported price: $33.92 / share

Sale disclosed

Keith S. Manchester

Director

Common Shares

Reported value: $11.07M
Reported price: $34.07 / share

Sale disclosed

Keith S. Manchester

Director

Common Shares

Reported value: $6.89M
Reported price: $34.44 / share

Sale disclosed

Keith S. Manchester

Director

Common Shares

Reported value: $20.75M
Reported price: $34.59 / share

Sale disclosed

Keith S. Manchester

Director

Common Shares

Reported value: $436.77K
Reported price: $35.28 / share

Sale disclosed

Keith S. Manchester

Director

Common Shares

Reported value: $7.09M
Reported price: $35.45 / share

Sale disclosed

Daniel Allen Gold

Director

Common Shares

Reported value: $10.2M
Reported price: $33.92 / share

Sale disclosed

Daniel Allen Gold

Director

Common Shares

Reported value: $11.07M
Reported price: $34.07 / share

Sale disclosed

Daniel Allen Gold

Director

Common Shares

Reported value: $6.89M
Reported price: $34.44 / share

Sale disclosed

Daniel Allen Gold

Director

Common Shares

Reported value: $20.75M
Reported price: $34.59 / share

Sale disclosed

Daniel Allen Gold

Director

Common Shares

Reported value: $436.77K
Reported price: $35.28 / share

Sale disclosed

Financial QVT

Other reporting owner

Common Shares

Reported value: $10.2M
Reported price: $33.92 / share

Sale disclosed

Financial QVT

Other reporting owner

Common Shares

Reported value: $11.07M
Reported price: $34.07 / share

Sale disclosed

Financial QVT

Other reporting owner

Common Shares

Reported value: $6.89M
Reported price: $34.44 / share

Sale disclosed

Financial QVT

Other reporting owner

Common Shares

Reported value: $20.75M
Reported price: $34.59 / share

Sale disclosed

Financial QVT

Other reporting owner

Common Shares

Reported value: $436.77K
Reported price: $35.28 / share

Sale disclosed

Mayukh Sukhatme

President & CIO

Common Shares

Reported value: $17.07M
Reported price: $34.13 / share

Sale disclosed

Mayukh Sukhatme

President & CIO

Common Shares

Reported value: $17.04M
Reported price: $34.08 / share

Sale disclosed

Eric Venker

President & Immunovant CEO

Common Shares

Reported value: $5.08M
Reported price: $33.05 / share

Sale disclosed

Eric Venker

President & Immunovant CEO

Common Shares

Reported value: $1.55M
Reported price: $33.51 / share

Sale disclosed

Eric Venker

President & Immunovant CEO

Common Shares

Reported value: $6.05M
Reported price: $30.27 / share

Sale disclosed

Eric Venker

President & Immunovant CEO

Common Shares

Reported value: $5.92M
Reported price: $29.59 / share

Sale disclosed

Matthew Gline

CEO

Common Shares

Reported value: $8.45M
Reported price: $29.16 / share

Sale disclosed

Jennifer Humes

Chief Accounting Officer

Common Shares

Reported value: $384.07K
Reported price: $28.37 / share

Sale disclosed

Meghan Fitzgerald

Director

Common Shares

Reported value: $1.92M
Reported price: $27.45 / share

Reporting insider	Security / transaction	Amount / price	Value	Traded / disclosed	Source
Director	Common SharesSale10b5-12 trades	17,750avg $36.10 / share	$640.86K	Oct 1Filed Oct 5 · 4d later	2 filings 16,850 @ $36.08 · $607.95KSEC filing 900 @ $36.57 · $32.91KSEC filing
President & Immunovant CEO	Common SharesSale10b5-1	200,000$36.62 / share	$7.32M	Sep 30Filed Oct 2 · 2d later	SEC filing
Director	Common SharesSale10b5-12 trades	4,938avg $39.74 / share	$196.23K	Sep 15Filed Sep 17 · 2d later	2 filings 4,338 @ $39.65 · $172KSEC filing 600 @ $40.38 · $24.23KSEC filing
Director	Common SharesSale10b5-12 trades	5,112avg $39.74 / share	$203.15K	Sep 15Filed Sep 17 · 2d later	2 filings 4,712 @ $39.68 · $186.97KSEC filing 400 @ $40.45 · $16.18KSEC filing
Director	Common SharesSale10b5-1	20,000$39.90 / share	$798K	Sep 8Filed Sep 10 · 2d later	SEC filing
President & Immunovant CEO	Common SharesSale10b5-12 trades	200,000avg $35.77 / share	$7.15M	Aug 28Filed Sep 1 · 4d later	2 filings 166,182 @ $35.63 · $5.92MSEC filing 33,818 @ $36.44 · $1.23MSEC filing
President & CIO	Common SharesSale	172,899$37.17 / share	$6.43M	Aug 19Filed Aug 21 · 2d later	SEC filing
President & CIO	Common SharesSale	17,519$37.30 / share	$653.46K	Aug 20Filed Aug 21 · 1d later	SEC filing
President & CIO	Common SharesSale	144,756$36.48 / share	$5.28M	Aug 21Filed Aug 21 · 0d later	SEC filing
President & CIO	Common SharesSale	243,177$36.23 / share	$8.81M	Aug 14Filed Aug 18 · 4d later	SEC filing
President & CIO	Common SharesSale	284,707$36.25 / share	$10.32M	Aug 17Filed Aug 18 · 1d later	SEC filing
President & CIO	Common SharesSale2 trades	136,942avg $36.73 / share	$5.03M	Aug 18Filed Aug 18 · 0d later	2 filings 105,141 @ $36.59 · $3.85MSEC filing 31,801 @ $37.18 · $1.18MSEC filing
President & Immunovant CEO	Common SharesSale10b5-1	200,000$34.95 / share	$6.99M	Jul 27Filed Jul 29 · 2d later	SEC filing
Director	Common SharesSale10b5-1	10,000$34.90 / share	$349K	Jun 30Filed Jul 2 · 2d later	SEC filing
Director	Common SharesSale10b5-12 trades	17,750avg $34.38 / share	$610.25K	Jun 29Filed Jul 1 · 2d later	2 filings 15,002 @ $34.32 · $514.87KSEC filing 2,748 @ $34.71 · $95.38KSEC filing
Director	Common SharesSale2 trades	625,783avg $34.00 / share	$21.28M	Jun 26Filed Jun 30 · 4d later	2 filings 300,783 @ $33.92 · $10.2MSEC filing 325,000 @ $34.07 · $11.07MSEC filing
Director	Common SharesSale2 trades	800,000avg $34.55 / share	$27.64M	Jun 29Filed Jun 30 · 1d later	2 filings 200,000 @ $34.44 · $6.89MSEC filing 600,000 @ $34.59 · $20.75MSEC filing
Director	Common SharesSale2 trades	212,380avg $35.44 / share	$7.53M	Jun 30Filed Jun 30 · 0d later	2 filings 12,380 @ $35.28 · $436.77KSEC filing 200,000 @ $35.45 · $7.09MSEC filing
Director	Common SharesSale2 trades	625,783avg $34.00 / share	$21.28M	Jun 26Filed Jun 30 · 4d later	2 filings 300,783 @ $33.92 · $10.2MSEC filing 325,000 @ $34.07 · $11.07MSEC filing
Director	Common SharesSale2 trades	800,000avg $34.55 / share	$27.64M	Jun 29Filed Jun 30 · 1d later	2 filings 200,000 @ $34.44 · $6.89MSEC filing 600,000 @ $34.59 · $20.75MSEC filing
Director	Common SharesSale	12,380$35.28 / share	$436.77K	Jun 30Filed Jun 30 · 0d later	SEC filing
Other reporting owner	Common SharesSale2 trades	625,783avg $34.00 / share	$21.28M	Jun 26Filed Jun 30 · 4d later	2 filings 300,783 @ $33.92 · $10.2MSEC filing 325,000 @ $34.07 · $11.07MSEC filing
Other reporting owner	Common SharesSale2 trades	800,000avg $34.55 / share	$27.64M	Jun 29Filed Jun 30 · 1d later	2 filings 200,000 @ $34.44 · $6.89MSEC filing 600,000 @ $34.59 · $20.75MSEC filing
Other reporting owner	Common SharesSale	12,380$35.28 / share	$436.77K	Jun 30Filed Jun 30 · 0d later	SEC filing
President & CIO	Common SharesSale	500,000$34.13 / share	$17.07M	Jun 25Filed Jun 29 · 4d later	SEC filing
President & CIO	Common SharesSale	500,000$34.08 / share	$17.04M	Jun 26Filed Jun 29 · 3d later	SEC filing
President & Immunovant CEO	Common SharesSale10b5-12 trades	200,000avg $33.16 / share	$6.63M	Jun 24Filed Jun 26 · 2d later	2 filings 153,766 @ $33.05 · $5.08MSEC filing 46,234 @ $33.51 · $1.55MSEC filing
President & Immunovant CEO	Common SharesSale10b5-1	200,000$30.27 / share	$6.05M	May 22Filed May 22 · 0d later	SEC filing
President & Immunovant CEO	Common SharesSale10b5-1	200,000$29.59 / share	$5.92M	Apr 20Filed Apr 22 · 2d later	SEC filing
CEO	Common SharesSale	289,774$29.16 / share	$8.45M	Apr 16Filed Apr 20 · 4d later	SEC filing
Chief Accounting Officer	Common SharesSale	13,538$28.37 / share	$384.07K	Apr 8Filed Apr 10 · 2d later	SEC filing
Director	Common SharesSale	70,000$27.45 / share	$1.92M	Mar 26Filed Mar 30 · 4d later	SEC filing

Congress transactions 3

All Congress filings

Sale disclosed

Roivant Sciences Ltd. - Common Shares (ROIV) · Stock

The filing reports a sale for a spouse.

Lisa McClainReporting House member

Reported amount: $1,001 – $15,000Reported range; exact amount not disclosed.
Trade date: October 31, 2025

Purchase disclosed

Roivant Sciences Ltd. - Common Shares (ROIV) · Stock

The filing reports a purchase for a spouse.

Lisa McClainReporting House member

Reported amount: $1,001 – $15,000Reported range; exact amount not disclosed.
Trade date: October 30, 2025

Sale disclosed

Roivant Sciences Ltd. - Common Shares (ROIV) · Stock

The filing reports a sale for a spouse.

Lisa McClainReporting House member

Reported amount: $1,001 – $15,000Reported range; exact amount not disclosed.
Trade date: October 30, 2025

Why this buying score?

No qualifying common-equity purchases

No eligible common-equity purchase is public by this cutoff within 180 transaction-date days. Other instruments, exercises and routine activity do not contribute purchase points.

+0 pts

This score describes qualifying insider purchases at issuer level. Read the methodology

Sources and coverage

Limited filing history · Market-wide discovery does not establish complete company history. View coverage

Source: SEC EDGAR · Form 4
Issuer CIK: 0001635088
Latest public acceptance: Oct 5, 2026, 10:05 PM UTC
Score calculated: Oct 8, 2026, 12:08 AM UTC
Parser: form4-parser-1.5
Classifier: form4-classifier-1.1
Scoring methodology: insider-experimental-1.1
Availability: Public filing time, not trade date

Open a transaction's SEC filing for the primary evidence. A code P may describe an open-market or private purchase; classification is not proof of intent.

Insider activity can have many explanations. Signal Strength is not a probability of profit or a recommendation to trade.

Reporting insider

Security / transaction

Amount / price

Value

Traded / disclosed

Source

Director

Common SharesSale10b5-12 trades

17,750avg $36.10 / share

$640.86K

Oct 1Filed Oct 5 · 4d later

2 filings

16,850 @ $36.08 · $607.95KSEC filing
900 @ $36.57 · $32.91KSEC filing

President & Immunovant CEO

Common SharesSale10b5-1

200,000$36.62 / share

$7.32M

Sep 30Filed Oct 2 · 2d later